Sign In
Buy VRTX
$466.79
+15.16 (+3.36%)
At Close: Jun 22, 2026
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up.
02:00am, Saturday, 20'th Jun 2026
Vertex Pharmaceuticals and Eli Lilly are both going after the non-opioid pain management market. Vertex Pharmaceuticals has a lead, but both drugmakers could be successful in this niche.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
06:51pm, Thursday, 18'th Jun 2026
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.63, denoting a -1.6% move from the preceding trading day.
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
07:00pm, Wednesday, 17'th Jun 2026
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $458.99, denoting a +1.28% move from the preceding trading day.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
10:02am, Wednesday, 17'th Jun 2026
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex
07:35am, Friday, 12'th Jun 2026
The death crosses flashing on both Hershey (NYSE: HSY | HSY Price Prediction) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring.
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
06:51pm, Thursday, 11'th Jun 2026
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $444.41, denoting a +2% move from the preceding trading day.
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
07:01pm, Wednesday, 10'th Jun 2026
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $435.76, signifying a -2.25% move from its prior day's close.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:22pm, Wednesday, 10'th Jun 2026
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
02:34pm, Monday, 08'th Jun 2026
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
12:00pm, Friday, 05'th Jun 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
11:16am, Thursday, 04'th Jun 2026
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?
12:36pm, Wednesday, 03'rd Jun 2026
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
12:10pm, Tuesday, 02'nd Jun 2026
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
